Trial Profile

First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AV 0113 (Primary) ; Temozolomide
Indications Glioblastoma
Focus Therapeutic Use
Acronyms GBM-Vax
Sponsors Activartis Biotech

Most Recent Events

17 Oct 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database.
30 May 2014 Interim results on overall survival presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
10 Apr 2013 Interim results presented at the 104th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com